WO2026057037 - COMBINATION OF PAN-RAS INHIBITOR AND FAK INHIBITOR
National phase entry is expected:
Publication Number
WO/2026/057037
Publication Date
19.03.2026
International Application No.
PCT/CN2025/121025
International Filing Date
12.09.2025
Title **
[English]
COMBINATION OF PAN-RAS INHIBITOR AND FAK INHIBITOR
[French]
COMBINAISON D'UN INHIBITEUR DE PAN-RAS ET D'UN INHIBITEUR DE FAK
[Chinese]
泛RAS抑制剂和FAK抑制剂的组合
Applicants **
SHANDONG SIMCERE ZAIMING BIOPHARMACEUTICAL CO., LTD.
Inventors
ZHOU, Feng
DOU, Huixia
YANG, Guimei
XUE, Liting
ZHU, Wei
CHEN, Xiang
LI, Zhengtao
TANG, Renhong
Priority Data
202411294000.7
14.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2887 | |
| EPO | Filing, Examination, Granting | 27783 | |
| Japan | Filing, Examination, Granting | 3077 | |
| South Korea | Filing, Examination, Granting | 4008 | |
| USA | Filing, Examination, Granting | 10140 |
Total:
47,895
Contact Us
Abstract[English]
A combined drug combination, drug composition or combination product of a pan-RAS (ON) inhibitor compound and a FAK (focal adhesion kinase) inhibitor, and a method for using the combined drug combination, drug composition or combination product to prepare a drug for preventing or treating a related pathological condition.[French]
L'invention concerne une association médicamenteuse combinée, une composition médicamenteuse ou un produit combiné d'un composé inhibiteur de pan-RAS (ON) et d'un inhibiteur de FAK (kinase d'adhésion focale), ainsi qu'un procédé d'utilisation de l'association médicamenteuse combinée, de la composition médicamenteuse ou du produit combiné pour préparer un médicament de prévention ou de traitement d'un état pathologique associé.[Chinese]
泛RAS（ON）抑制剂化合物与FAK（Focal Adhesion Kinase,FAK）抑制剂的联用药物组合、药物组合物或组合产品，以及使用联用药物组合、药物组合物或组合产品制备预防或治疗相关病理学病症的药物的方法。